Recent data on ProMetic's orally active drug candidates demonstrates efficacy in diabetic kidney disease and other fibrotic models

LAVAL, QUEBEC, CANADA--(Marketwire - Nov. 1, 2012) - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic" or the "Corporation") is presenting today new and positive data on two of its orally active anti-fibrotic drug candidates at the annual Meeting of the American Society of Nephrology in San Diego, California.

Diabetic nephropathy is increasing in incidence and is now the number one cause of end-stage renal disease. In a gold standard animal model used to mimic the long term detrimental effects of diabetes on the kidney and the liver, ProMetic's once a day oral treatment with PBI-4050 demonstrated a significant reduction in kidney hyperfiltration, proteinuria and hepatic steatosis. These results suggest that PBI-4050 could be potentially be used as a novel therapy for diabetic kidney disease and liver steatosis. PBI-4050 has been shown to treat fibrosis in several different animal models and is now being prepared to enter into clinical development in 2013.

Other interesting data being presented at the ASN confirms the effect of ProMetic's drug candidates on interstitial fibroblasts which are the principal cause of organ fibrosis.

"TGF-β-stimulated fibroblasts secrete connective tissue growth factor (CTGF) which functions as a downstream mediator of TGF-β action on fibroblastic cell types are important in collagen production. ProMetic's drug candidates have demonstrated the inhibition of CTGF and collagen production in murine and human fibroblasts and consequently to reduce kidney fibrosis in 5/6-nephrectomized rats and unilateral ureteral obstruction models", said Dr. Lyne Gagnon, ProMetic's Director of Research and Developement, Biology.

Dr. Lyne Gagnon, ProMetic's Director of Research and Development, Biology, and Dr. Martin Leduc, will be presenting data during two poster sessions at the following times:

Thursday, November 1, 2012, 10:00 AM - 12:00 PM (PST) Poster Session Diabetes: Basic - Cell Biology, Models -1, # TH-PO482

3175 "Oral Treatment with a Novel First-in-Class Anti-Fibrotic Compound PBI-4050 Reduces Kidney Hyperfiltration, Proteinuria and Hepatic Steatosis in the Diabetic db/db Mouse Model"

Thursday, November 1, 2012, 10:00 AM - 12:00 PM (PST) Poster Session Pathobiology:

Basic/Experimental Pathology - I # TH-PO969

3170 "PBI-4419, a Novel First-in-Class Anti-Fibrotic Compound, Inhibits CTGF and Collagen Production in Murine and Human Fibroblasts and Reduces Kidney Fibrosis in 5/6-Nephrectomized and Unilateral Ureteral Obstruction Rat Models"


Company definitely on a roll... good luck.